青年人肺癌临床及病理特点分析

doi:10.3969/j.issn.1002-3070.2009.04.019

PRACTICAL ONCOLOGY JOURNAL ›› 2009, Vol. 23 ›› Issue (4): 357-358.doi: 10.3969/j.issn.1002-3070.2009.04.019

Previous Articles Next Articles

Received:2009-06-18 Online:2009-08-20 Published:2012-02-21

Abstract

CLC Number:

R734.2

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.3969/j.issn.1002-3070.2009.04.019

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2009/V23/I4/357

[1]	LU Juping, HU Jun, DENG Yongming, LIAO Shufang. Downregulation of FKBP4 inhibits the malignant progression of non-small cell lung cancer by blocking the PI3K/Akt/mTOR signaling pathway [J]. Journal of Practical Oncology, 2025, 39(3): 184-190.
[2]	LI Caizheng, ZHENG Jing, SU Qiaoli. Advance progress in immunotherapy for unresectable locally advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2025, 39(1): 67-72.
[3]	CHEN Xingyan, LI Xue, FU Qiang. Research progress of RNA methylation in lung cancer [J]. Journal of Practical Oncology, 2024, 38(6): 421-426.
[4]	HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(5): 306-312.
[5]	XU Lingyan, LI Qianni, LI Jian, YAO Xuepei, LIU Meina. Analysis for the impact of the first hospitalization days on treatment quality in patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(4): 221-226.
[6]	YAO Xuepei, BAI Shanqi, LIU Meina. Analysis of factors influencing treatment quality of non-small cell lung cancer based on causal diagram model [J]. Journal of Practical Oncology, 2024, 38(4): 227-234.
[7]	MA Na, LIU Jie. Analysis of lung cancer incidence and mortality in Hedong district,Tianjin,from 2015 to 2020 [J]. Journal of Practical Oncology, 2024, 38(4): 241-245.
[8]	CHENG Yongming, DONG Huanhuan, XU Hui. Hsa-let-7b-5p inhibits proliferation,migration and invasion in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(3): 157-167.
[9]	WANG Wenbo, BAI Haixin, ZHANG Tan, NIU Li. Propofol inhibits glycolysis and tumor progression in lung cancer through GLUT4 [J]. Journal of Practical Oncology, 2024, 38(2): 104-111.
[10]	BO Yun, HANG Wenlu, ZUO Shurun, Dong Yuan, LI Haiquan. Effects of long non-coding RNA OTUD6B-AS1 on proliferation,invasion and migration of lung adenocarcinoma A549 cells [J]. Journal of Practical Oncology, 2024, 38(1): 13-17.
[11]	ZHANG Xuan, LI Xin, ZHAO Kang. Relationship between serum inflammatory markers and prognosis of advanced non-small cell lung cancer patients treated with first-line immunosuppressants [J]. Journal of Practical Oncology, 2024, 38(1): 37-44.
[12]	CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 383-388.
[13]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[14]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[15]	CHEN Junhui, LIU Siyu, HE Changjun. Research progress of RUNX1 in lung cancer [J]. Journal of Practical Oncology, 2022, 36(6): 576-579.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments